Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Prothena Corp (PRTA)

Prothena Corp (PRTA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 338,572
  • Shares Outstanding, K 53,827
  • Annual Sales, $ 135,160 K
  • Annual Income, $ -122,310 K
  • EBIT $ -139 M
  • EBITDA $ -135 M
  • 60-Month Beta 0.01
  • Price/Sales 2.56
  • Price/Cash Flow N/A
  • Price/Book 0.79

Options Overview Details

View History
  • Implied Volatility 101.70% ( -45.75%)
  • Historical Volatility 116.45%
  • IV Percentile 64%
  • IV Rank 18.40%
  • IV High 323.72% on 05/21/25
  • IV Low 51.64% on 09/13/24
  • Put/Call Vol Ratio 20.79
  • Today's Volume 1,155
  • Volume Avg (30-Day) 1,010
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 23,735
  • Open Int (30-Day) 31,268

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate -1.06
  • Number of Estimates 6
  • High Estimate -0.50
  • Low Estimate -1.47
  • Prior Year 1.22
  • Growth Rate Est. (year over year) -186.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.95 +31.72%
on 06/13/25
6.66 -2.18%
on 07/08/25
+1.11 (+20.52%)
since 06/06/25
3-Month
4.32 +50.93%
on 05/28/25
10.79 -39.57%
on 04/09/25
-3.96 (-37.79%)
since 04/08/25
52-Week
4.32 +50.93%
on 05/28/25
25.42 -74.35%
on 07/25/24
-13.66 (-67.69%)
since 07/08/24

Most Recent Stories

More News
Prothena: Q1 Earnings Snapshot

Prothena: Q1 Earnings Snapshot

PRTA : 6.52 (+3.66%)
Prothena: Q4 Earnings Snapshot

Prothena: Q4 Earnings Snapshot

PRTA : 6.52 (+3.66%)
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study

Roche RHHBY announced data from the phase IIb PADOVA study which evaluated its investigational monoclonal antibody, prasinezumab, for treating people with early-stage Parkinson’s disease.The double-blind...

CSTL : 19.76 (+1.54%)
PRTA : 6.52 (+3.66%)
RHHBY : 40.0900 (-0.57%)
SPRO : 2.94 (+1.38%)
Prothena: Q3 Earnings Snapshot

Prothena: Q3 Earnings Snapshot

PRTA : 6.52 (+3.66%)
Prothena: Q2 Earnings Snapshot

Prothena: Q2 Earnings Snapshot

PRTA : 6.52 (+3.66%)
Prothena Reports First Quarter 2023 Financial Results and Business Highlights

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial...

PRTA : 6.52 (+3.66%)
Prothena to Report First Quarter 2023 Financial Results on May 4

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 6.52 (+3.66%)
Prothena to Participate in 2023 Bank of America Healthcare Conference

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that...

PRTA : 6.52 (+3.66%)
Walgreens and Prothena Partner to Increase Access and Enrollment in Alzheimer’s Disease Clinical Trial

Walgreens and Prothena today announced a collaboration to accelerate patient identification and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial evaluating the safety...

WBA : 11.52 (-0.26%)
PRTA : 6.52 (+3.66%)
Prothena Presents New Preclinical Data Supporting Best-in-Class Profile of PRX012, a Next-Generation Anti-Amyloid Beta Antibody, at AD/PD 2023

Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced new...

PRTA : 6.52 (+3.66%)

Business Summary

Prothena Corp. plc, being a clinical-stage neuroscience company, focused on the development of novel therapeutic therapies for life-threatening diseases. Its wholly owned programs include birtamimab for the potential treatment of AL amyloidosis, PRX004 for the potential treatment of ATTR amyloidosis...

See More

Key Turning Points

3rd Resistance Point 7.07
2nd Resistance Point 6.87
1st Resistance Point 6.69
Last Price 6.52
1st Support Level 6.32
2nd Support Level 6.12
3rd Support Level 5.94

See More

52-Week High 25.42
Fibonacci 61.8% 17.36
Fibonacci 50% 14.87
Fibonacci 38.2% 12.38
Last Price 6.52
52-Week Low 4.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar